Thus, FOXC1 emerges as a potential prognostic indicator, while the IGF-1-FOXC1-IGF-1R oncogenic loop stands out as a prospective therapeutic avenue for mitigating FOXC1-induced ESCC stemness. This evidence concerns the gene IGF1 and esophageal squamous cell carcinoma.